The synthetic blood substitutes and blood products market size has grown rapidly in recent years. It will grow from $7.6 billion in 2025 to $8.81 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to blood donation shortages, trauma and surgery demand, transfusion-transmitted infection risks, growth in cardiovascular surgeries, military medical needs.
The synthetic blood substitutes and blood products market size is expected to see rapid growth in the next few years. It will grow to $15.7 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to rising trauma cases, aging population surgeries, innovation in recombinant factors, demand for universal blood substitutes, emergency preparedness investments. Major trends in the forecast period include development of oxygen-carrying blood substitutes, emergency trauma blood alternatives, reduced dependence on donor blood, extended shelf-life blood products, military and disaster medicine adoption.
The increasing prevalence of chronic diseases is anticipated to drive the growth of the synthetic blood substitutes and blood products market in the coming years. Chronic diseases are long-term conditions that are typically manageable but not curable, often lasting a year or more and requiring continuous medical care. The rising incidence of chronic diseases is driven by factors such as an aging population, unhealthy lifestyle habits, and increased life expectancy. Synthetic blood substitutes and blood products play an important role in managing chronic diseases by addressing issues related to blood loss, anemia, and organ function, which are common among patients with long-term conditions. For example, in March 2025, according to the Office for Health Improvement & Disparities (OHID), a UK-based unit of the Department of Health and Social Care, the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over in England reached 7% in March 2024, up from 6.8% in March 2023. Therefore, the rising prevalence of chronic diseases is fueling the growth of the synthetic blood substitutes and blood products market.
Companies in the synthetic blood substitutes and blood products market are focusing on innovations such as lab-grown blood vessels to improve emergency medical care, enhance trauma treatment, and address shortages of donor blood and tissues. Lab-grown blood vessels, engineered from human or synthetic cells, mimic the structure and function of natural arteries and veins, making them valuable for applications such as trauma repair, dialysis, and cardiovascular surgery. For instance, in December 2024, Humacyte Global, Inc., a US-based clinical-stage biotechnology company, received FDA approval for Symvess, an off-the-shelf bioengineered blood vessel implant designed for trauma patients requiring urgent revascularization. Symvess offers a safer alternative to traditional vein harvesting or synthetic grafts, restoring blood flow and preserving limbs after severe injuries.
In December 2024, GVS S.p.A., an Italy-based plastic fabrication company, acquired blood-related assets from Haemonetics Corporation for $67.1 million. This acquisition strengthens GVS’s focus on plasma and hospital-based blood management solutions while expanding its product offerings in the blood collection and filtration market. Haemonetics Corporation, a US-based company, specializes in developing and selling blood management devices, including artificial blood substitutes and other blood-related products.
Major companies operating in the synthetic blood substitutes and blood products market are Takeda Pharmaceutical Company Limited, Fresenius Kabi AG, Baxter International Inc., Octapharma AG, Green Cross Corporation, Alliance Pharmaceutical Corporation, Hemosol Inc., Sanguine Corporation, Sangart Inc., Biopure Corporation, Tenex Therapeutics, Velico Medical, Hemarina S.A., KaloCyte Inc., Aurum Biosciences Limited, SpheriTech Limited, Dendritech Inc., HbO2 Therapeutics LLC, HemoBioTech Inc., Somatogen Inc.
North America was the largest region in the synthetic blood substitutes and blood products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the synthetic blood substitutes and blood products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the synthetic blood substitutes and blood products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the synthetic blood substitutes and blood products market by increasing costs of bioprocessing equipment, recombinant materials, and pharmaceutical-grade inputs. Hemoglobin-based oxygen carriers and recombinant factor segments are most impacted, particularly in import-dependent regions such as Asia-Pacific and Latin America. While tariffs raise production expenses, they have also encouraged domestic biomanufacturing, regional R&D investments, and supply-chain resilience in critical blood alternatives.
The synthetic blood substitutes and blood products market research report is one of a series of new reports that provides synthetic blood substitutes and blood products market statistics, including synthetic blood substitutes and blood products industry global market size, regional shares, competitors with a synthetic blood substitutes and blood products market share, detailed synthetic blood substitutes and blood products market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic blood substitutes and blood products industry. This synthetic blood substitutes and blood products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Synthetic blood substitutes and blood products are innovative medical solutions designed to replicate the functions of human blood, such as oxygen transport and clotting, to assist patients in need of blood transfusions. Developed through biotechnological processes, these products play a vital role in addressing blood shortages and offering alternatives for emergencies or individuals with specific medical conditions.
The primary categories of synthetic blood substitutes and blood products include perfluorocarbon-based products (PFCs), hemoglobin-based oxygen carriers, synthetic platelets, recombinant factors, and blood expanders. Perfluorocarbon-based products (PFCs) function as synthetic oxygen carriers capable of dissolving and transporting oxygen and carbon dioxide within the bloodstream, serving as blood substitutes in medical treatments. These products are utilized for various purposes, including the treatment of cardiovascular diseases, anemia, organ transplants, injuries, and trauma. Additionally, they are used by multiple end users, such as hospitals and clinics, blood banks, and other medical institutions.
The synthetic blood substitutes and blood products market consists of sales of artificial blood substitutes, blood plasma substitutes, and blood plasma products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The synthetic blood substitutes and blood products market size is expected to see rapid growth in the next few years. It will grow to $15.7 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to rising trauma cases, aging population surgeries, innovation in recombinant factors, demand for universal blood substitutes, emergency preparedness investments. Major trends in the forecast period include development of oxygen-carrying blood substitutes, emergency trauma blood alternatives, reduced dependence on donor blood, extended shelf-life blood products, military and disaster medicine adoption.
The increasing prevalence of chronic diseases is anticipated to drive the growth of the synthetic blood substitutes and blood products market in the coming years. Chronic diseases are long-term conditions that are typically manageable but not curable, often lasting a year or more and requiring continuous medical care. The rising incidence of chronic diseases is driven by factors such as an aging population, unhealthy lifestyle habits, and increased life expectancy. Synthetic blood substitutes and blood products play an important role in managing chronic diseases by addressing issues related to blood loss, anemia, and organ function, which are common among patients with long-term conditions. For example, in March 2025, according to the Office for Health Improvement & Disparities (OHID), a UK-based unit of the Department of Health and Social Care, the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over in England reached 7% in March 2024, up from 6.8% in March 2023. Therefore, the rising prevalence of chronic diseases is fueling the growth of the synthetic blood substitutes and blood products market.
Companies in the synthetic blood substitutes and blood products market are focusing on innovations such as lab-grown blood vessels to improve emergency medical care, enhance trauma treatment, and address shortages of donor blood and tissues. Lab-grown blood vessels, engineered from human or synthetic cells, mimic the structure and function of natural arteries and veins, making them valuable for applications such as trauma repair, dialysis, and cardiovascular surgery. For instance, in December 2024, Humacyte Global, Inc., a US-based clinical-stage biotechnology company, received FDA approval for Symvess, an off-the-shelf bioengineered blood vessel implant designed for trauma patients requiring urgent revascularization. Symvess offers a safer alternative to traditional vein harvesting or synthetic grafts, restoring blood flow and preserving limbs after severe injuries.
In December 2024, GVS S.p.A., an Italy-based plastic fabrication company, acquired blood-related assets from Haemonetics Corporation for $67.1 million. This acquisition strengthens GVS’s focus on plasma and hospital-based blood management solutions while expanding its product offerings in the blood collection and filtration market. Haemonetics Corporation, a US-based company, specializes in developing and selling blood management devices, including artificial blood substitutes and other blood-related products.
Major companies operating in the synthetic blood substitutes and blood products market are Takeda Pharmaceutical Company Limited, Fresenius Kabi AG, Baxter International Inc., Octapharma AG, Green Cross Corporation, Alliance Pharmaceutical Corporation, Hemosol Inc., Sanguine Corporation, Sangart Inc., Biopure Corporation, Tenex Therapeutics, Velico Medical, Hemarina S.A., KaloCyte Inc., Aurum Biosciences Limited, SpheriTech Limited, Dendritech Inc., HbO2 Therapeutics LLC, HemoBioTech Inc., Somatogen Inc.
North America was the largest region in the synthetic blood substitutes and blood products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the synthetic blood substitutes and blood products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the synthetic blood substitutes and blood products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the synthetic blood substitutes and blood products market by increasing costs of bioprocessing equipment, recombinant materials, and pharmaceutical-grade inputs. Hemoglobin-based oxygen carriers and recombinant factor segments are most impacted, particularly in import-dependent regions such as Asia-Pacific and Latin America. While tariffs raise production expenses, they have also encouraged domestic biomanufacturing, regional R&D investments, and supply-chain resilience in critical blood alternatives.
The synthetic blood substitutes and blood products market research report is one of a series of new reports that provides synthetic blood substitutes and blood products market statistics, including synthetic blood substitutes and blood products industry global market size, regional shares, competitors with a synthetic blood substitutes and blood products market share, detailed synthetic blood substitutes and blood products market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic blood substitutes and blood products industry. This synthetic blood substitutes and blood products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Synthetic blood substitutes and blood products are innovative medical solutions designed to replicate the functions of human blood, such as oxygen transport and clotting, to assist patients in need of blood transfusions. Developed through biotechnological processes, these products play a vital role in addressing blood shortages and offering alternatives for emergencies or individuals with specific medical conditions.
The primary categories of synthetic blood substitutes and blood products include perfluorocarbon-based products (PFCs), hemoglobin-based oxygen carriers, synthetic platelets, recombinant factors, and blood expanders. Perfluorocarbon-based products (PFCs) function as synthetic oxygen carriers capable of dissolving and transporting oxygen and carbon dioxide within the bloodstream, serving as blood substitutes in medical treatments. These products are utilized for various purposes, including the treatment of cardiovascular diseases, anemia, organ transplants, injuries, and trauma. Additionally, they are used by multiple end users, such as hospitals and clinics, blood banks, and other medical institutions.
The synthetic blood substitutes and blood products market consists of sales of artificial blood substitutes, blood plasma substitutes, and blood plasma products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Synthetic Blood Substitutes and Blood Products Market Characteristics
3. Synthetic Blood Substitutes and Blood Products Market Supply Chain Analysis
4. Global Synthetic Blood Substitutes and Blood Products Market Trends and Strategies
5. Synthetic Blood Substitutes and Blood Products Market Analysis of End Use Industries
7. Global Synthetic Blood Substitutes and Blood Products Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Synthetic Blood Substitutes and Blood Products Total Addressable Market (TAM) Analysis for the Market
9. Synthetic Blood Substitutes and Blood Products Market Segmentation
10. Synthetic Blood Substitutes and Blood Products Market Regional and Country Analysis
11. Asia-Pacific Synthetic Blood Substitutes and Blood Products Market
12. China Synthetic Blood Substitutes and Blood Products Market
13. India Synthetic Blood Substitutes and Blood Products Market
14. Japan Synthetic Blood Substitutes and Blood Products Market
15. Australia Synthetic Blood Substitutes and Blood Products Market
16. Indonesia Synthetic Blood Substitutes and Blood Products Market
17. South Korea Synthetic Blood Substitutes and Blood Products Market
18. Taiwan Synthetic Blood Substitutes and Blood Products Market
19. South East Asia Synthetic Blood Substitutes and Blood Products Market
20. Western Europe Synthetic Blood Substitutes and Blood Products Market
21. UK Synthetic Blood Substitutes and Blood Products Market
22. Germany Synthetic Blood Substitutes and Blood Products Market
23. France Synthetic Blood Substitutes and Blood Products Market
24. Italy Synthetic Blood Substitutes and Blood Products Market
25. Spain Synthetic Blood Substitutes and Blood Products Market
26. Eastern Europe Synthetic Blood Substitutes and Blood Products Market
27. Russia Synthetic Blood Substitutes and Blood Products Market
28. North America Synthetic Blood Substitutes and Blood Products Market
29. USA Synthetic Blood Substitutes and Blood Products Market
30. Canada Synthetic Blood Substitutes and Blood Products Market
31. South America Synthetic Blood Substitutes and Blood Products Market
32. Brazil Synthetic Blood Substitutes and Blood Products Market
33. Middle East Synthetic Blood Substitutes and Blood Products Market
34. Africa Synthetic Blood Substitutes and Blood Products Market
36. Synthetic Blood Substitutes and Blood Products Market Competitive Landscape and Company Profiles
37. Synthetic Blood Substitutes and Blood Products Market Other Major and Innovative Companies
40. Synthetic Blood Substitutes and Blood Products Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Synthetic Blood Substitutes And Blood Products Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses synthetic blood substitutes and blood products market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for synthetic blood substitutes and blood products? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The synthetic blood substitutes and blood products market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Perfluorocarbon Based Product (PFC); Haemoglobin Based Oxygen Carrier; Synthetic Platelet; Recombinant Factor; Blood Expander2) By Application: Cardiovascular Diseases; Anaemia; Organ Transplant; Injury and Trauma; Other Applications
3) By End-User: Hospitals And Clinics; Blood Banks; Other End users
Subsegments:
1) By Perfluorocarbon Based Product (PFC): Emulsion-Based Products; Non-Emulsion-Based Products2) By Haemoglobin Based Oxygen Carrier: Polymerized Hemoglobin-Based Products; Crosslinked Hemoglobin-Based Products
3) By Synthetic Platelet: Platelet Substitutes; Platelet Aggregation Inhibitors
4) By Recombinant Factor: Recombinant Factor VIII; Recombinant Factor IX; Other Recombinant Factors
5) By Blood Expander: Colloid Solutions; Crystalloid Solutions
Companies Mentioned: Takeda Pharmaceutical Company Limited; Fresenius Kabi AG; Baxter International Inc.; Octapharma AG; Green Cross Corporation; Alliance Pharmaceutical Corporation; Hemosol Inc.; Sanguine Corporation; Sangart Inc.; Biopure Corporation; Tenex Therapeutics; Velico Medical; Hemarina S.A.; KaloCyte Inc.; Aurum Biosciences Limited; SpheriTech Limited; Dendritech Inc.; HbO2 Therapeutics LLC; HemoBioTech Inc.; Somatogen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Synthetic Blood Substitutes And Blood Products market report include:- Takeda Pharmaceutical Company Limited
- Fresenius Kabi AG
- Baxter International Inc.
- Octapharma AG
- Green Cross Corporation
- Alliance Pharmaceutical Corporation
- Hemosol Inc.
- Sanguine Corporation
- Sangart Inc.
- Biopure Corporation
- Tenex Therapeutics
- Velico Medical
- Hemarina S.A.
- KaloCyte Inc.
- Aurum Biosciences Limited
- SpheriTech Limited
- Dendritech Inc.
- HbO2 Therapeutics LLC
- HemoBioTech Inc.
- Somatogen Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 8.81 Billion |
| Forecasted Market Value ( USD | $ 15.7 Billion |
| Compound Annual Growth Rate | 15.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
